Structure via PubChem · Public domain (PubChem)
mavoglurant
Sign in to saveAlso known as AFQ056, AFQ-056
Mavoglurant (developmental code name AFQ-056) is an experimental drug candidate for the treatment of fragile X syndrome and other conditions. It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGluR5).
In the Vinony graph
Within Vinony's link graph, mavoglurant is referenced by 127 other articles, and connects out to medication, nervous system and digital object identifier.
Vinony files it under Alkyne derivatives, Carbamates and Chembox image size set.
Its subject is documented across 5 Wikipedia language editions.
Chemical data
- Formula
- C19H23NO3
- Molecular weight
- 313.4 g/mol
- IUPAC name
- methyl (3aR,4S,7aR)-4-hydroxy-4-[2-(3-methylphenyl)ethynyl]-3,3a,5,6,7,7a-hexahydro-2H-indole-1-carboxylate
- SMILES
- CC1=CC(=CC=C1)C#C[C@@]2(CCC[C@@H]3[C@H]2CCN3C(=O)OC)O
- InChIKey
- ZFPZEYHRWGMJCV-ZHALLVOQSA-N
- XLogP
- 2.9
- Polar surface area
- 49.8 Ų
- H-bond donors
- 1
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
- Indications
- obsessive-compulsive disorder, liver disease, cocaine dependence, gastroesophageal reflux disease
via ChEMBL · EBI
Wikidata facts
- Mass
- 313.168
Show 4 more facts
- chemical formula
- C₁₉H₂₃NO₃
- isomeric SMILES
- CC1=CC=CC(=C1)C#C[C@@]2(CCC[C@@H]3[C@H]2CCN3C(=O)OC)O
- canonical SMILES
- CC1=CC=CC(=C1)C#CC2(CCCC3C2CCN3C(=O)OC)O
- World Health Organisation international non-proprietary name
- mavoglurant
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Mavoglurant (developmental code name AFQ-056) is an experimental drug candidate for the treatment of fragile X syndrome and other conditions. It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGluR5).
Mavoglurant was under development by Novartis and reached phase II and phase III clinical trials. Phase IIb/III dose finding and evaluation trials for fragile X-syndrome were discontinued by the end of 2014. Otherwise, it would have been the first drug to treat the underlying disorder instead of the symptoms of fragile X syndrome. Mavoglurant was also in phase II clinical trials for Levodopa-induced dyskinesia. In 2007, Norvartis had conducted a clinical study to assess its ability of reducing cigarette smoking, but no results had been published up till now. Novartis was conducting a clinical trial with this drug on obsessive–compulsive disorder.
Excerpted from Wikipedia’s “mavoglurant” article, available under the CC BY-SA 4.0 licence.